Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2005

View Archived Issues

Human Genome Sciences monoclonal antibodies presented at recent congresses

Cell-based vaccine shows promise in prostate cancer

Eculizumab demonstrates long-term efficacy in paroxysmal nocturnal hemoglobinuria

Pioglitazone improves lipids more than rosiglitazone in type 2 diabetes patients

Tacrolimus ointment evaluated in allergic diseases

NeuroVax boosts FOXP3 expression in multiple sclerosis patients

Companies patent new therapies for depression, psychosis, etc.

Novel agents for the treatment of neurological disorders in early development

DA-9601 ameliorates asthma in mice

CBIQ activates mutant form of CFTR present in 75% of cystic fibrosis patients

Novel approach for asthma treatment via neurotrophin receptor antagonism

Lilly to discontinue four insulin products

NV-52 enters phase I for inflammatory bowel disease

NCI accepts Ceragenix cationic steroid antibiotic compounds for testing

Meridian Bioscience awarded license for parvovirus B19 vaccine

GlaxoSmithKline exercises option to LymphoStat

Development of ATL-146e for reperfusion injury supported by SBIR grant

PTC-124 receives orphan drug designations in Europe

Napo and Glenmark collaborate on crofelemer development

New data on gaboxadol in the treatment of primary insomnia

A gemcitabine-containing regimen improves quality of life of patients with early NSCLC

Phase II study of Prostvac-VF completes enrollment

FDA requests safety analysis for FTY-720

SPA for phase III study of Tocosol Paclitaxel in breast cancer

Sorafenib NDA filing complete

Novartis submits new Femara applications in U.S., Europe

Preos NDA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...